MX2023012460A - Una forma de tafamidis en estado solido y un proceso para su preparacion. - Google Patents

Una forma de tafamidis en estado solido y un proceso para su preparacion.

Info

Publication number
MX2023012460A
MX2023012460A MX2023012460A MX2023012460A MX2023012460A MX 2023012460 A MX2023012460 A MX 2023012460A MX 2023012460 A MX2023012460 A MX 2023012460A MX 2023012460 A MX2023012460 A MX 2023012460A MX 2023012460 A MX2023012460 A MX 2023012460A
Authority
MX
Mexico
Prior art keywords
preparation
tafamidis
solid state
state form
crystalline form
Prior art date
Application number
MX2023012460A
Other languages
English (en)
Spanish (es)
Inventor
Massimo Zampieri
Piero Paravidino
Giuseppe Barreca
Luca Carcone
Daniele Pengo
Liming Huang
Original Assignee
Quim Sintetica S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quim Sintetica S A filed Critical Quim Sintetica S A
Publication of MX2023012460A publication Critical patent/MX2023012460A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
MX2023012460A 2021-04-26 2022-04-22 Una forma de tafamidis en estado solido y un proceso para su preparacion. MX2023012460A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21382362.8A EP4083027A1 (en) 2021-04-26 2021-04-26 A solid state form of tafamidis and a process for its preparation
PCT/EP2022/060716 WO2022229026A1 (en) 2021-04-26 2022-04-22 A solid state form of tafamidis and a process for its preparation

Publications (1)

Publication Number Publication Date
MX2023012460A true MX2023012460A (es) 2023-12-14

Family

ID=75746555

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012460A MX2023012460A (es) 2021-04-26 2022-04-22 Una forma de tafamidis en estado solido y un proceso para su preparacion.

Country Status (8)

Country Link
US (1) US20240208915A1 (https=)
EP (2) EP4083027A1 (https=)
JP (1) JP2024515770A (https=)
CN (1) CN117255781A (https=)
BR (1) BR112023022116A2 (https=)
CA (1) CA3216325A1 (https=)
MX (1) MX2023012460A (https=)
WO (1) WO2022229026A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250042864A1 (en) * 2021-11-17 2025-02-06 Teva Pharmaceuticals International Gmbh Solid state form of tafamidis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2800237C (en) 2002-12-19 2016-05-17 The Scripps Research Institute Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
RU2565066C2 (ru) * 2010-04-21 2015-10-20 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Производные 1-(2-фторбифенил-4-ил)-алкилкарбоновой кислоты для лечения транстиретинового амилоидоза
RU2586330C2 (ru) 2011-09-16 2016-06-10 Пфайзер Инк. Твердые формы ингибитора диссоциации транстиретина
PT4349406T (pt) 2014-09-08 2026-02-04 Pfizer Formas sólidas cristalinas de 6-carboxi-2-(3,5-diclorofenil)-benzoxazol para utilização como medicamento
GB2571950A (en) 2018-03-13 2019-09-18 Azad Pharma Ag New polymorph and new path to synthesize tafamidis
EP3969443B1 (en) 2019-05-16 2024-11-20 Teva Pharmaceuticals International GmbH Solid state forms of tafamidis and salts thereof
US20220251052A1 (en) * 2019-07-04 2022-08-11 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof
WO2021019448A1 (en) 2019-08-01 2021-02-04 Honour (R&D) Process for the preparation of transthyretin dissociation inhibitor
WO2021152623A1 (en) * 2020-01-27 2021-08-05 Dr. Reddy’S Laboratories Limited Improved processes for the preparation of tafamidis and its meglumine salt
US12522573B2 (en) * 2020-10-19 2026-01-13 Alivus Life Sciences Limited Process for preparation of tafamidis and salts thereof

Also Published As

Publication number Publication date
US20240208915A1 (en) 2024-06-27
WO2022229026A1 (en) 2022-11-03
BR112023022116A2 (pt) 2024-01-09
EP4083027A1 (en) 2022-11-02
CN117255781A (zh) 2023-12-19
EP4330237A1 (en) 2024-03-06
JP2024515770A (ja) 2024-04-10
CA3216325A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
IL318601A (en) Improved synthesis of a key intermediate of the KRAS inhibitor compound G12C
EA201990688A1 (ru) Полиморфные формы соединения, представляющего собой ингибитор киназ, содержащая их фармацевтическая композиция, способ их получения и их применение
AR063710A1 (es) Proceso para la preparacion de acido 6-(3-cloro-2-fluorbencil)-1-[(s)-1-hidroximetil-2-metilpropil]-7-metoxi-4-oxo-1, 4-dihidroquinolon-3-carboxilico como inhibidores de integrasa del hiv e intermediarios de sintesis del mismo y composiciones que lo comprenden.
WO2012065114A3 (en) Polyketal adducts, methods of manufacture and uses thereof
MX2023000059A (es) Metodo de preparacion de compuesto de fenilisoxazolina.
MX388841B (es) Procesos para preparar acido 3-(3-(3,5-dimetil-1h-pirazol-4-il)propoxi)-4- 5-fluorobenzoico (ag-10), sus compuestos intermedios, y sales del mismo
ZA202311094B (en) Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use
MX2023012460A (es) Una forma de tafamidis en estado solido y un proceso para su preparacion.
SI1601653T1 (sl) Postopek za pripravo substituiranih estrov nikotinske kisline
MX378594B (es) Procedimiento e intermedios para la 6,7-alfa-epoxidacion de 4,6-dienos esteroideos
DK1877384T3 (da) Fremgangsmåde til fremstilling af eventuelt 2-substituerede 1,6-dihydro-6-oxo-4-pyrimidincarboxylsyrer
WO2020127208A8 (en) Pharmaceutical process and intermediates
WO2021016220A3 (en) Synthesis of substituted furans
WO2020016847A3 (en) Purification process for preparation of eribulin and intermediates thereof
PH12021552284A1 (en) D-metyrosine compositions and methods for preparing same
MX2025006770A (es) Nueva forma cristalina de magnesio-serinato y metodo para producir la misma
MX2025000464A (es) Forma cristalina de un esteroide neuroactivo
WO2024186788A3 (en) High purity nitric oxide releasing compounds and methods of preparing same
PH12022552441A1 (en) Tall oil derived glycidyl esters and process of making the same
PH12021550022A1 (en) Spirobiindane derivatives and a process for preparation thereof
MX2023005713A (es) Nuevo proceso para la elaboracion de derivados de tetrazol.
MX2025009371A (es) Forma cristalina de derivado de sulfonamida y metodo de preparacion para ello
GB858792A (en) New pyridazine derivatives and processes for their manufacture
SE7510787L (sv) Nya kvevehaltiga, polycykliska foreningar, salter derav och deras optiska antipoder, jemte sett for deras framstellning
MX2024007679A (es) Compuestos intermedios cristalinos.